Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,145.60
(
0.54%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.69
(
2.43%
)
Bitcoin
74,772.06
(
-0.10%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 142515

Thursday, 06/21/2012 6:01:29 PM

Thursday, June 21, 2012 6:01:29 PM

Post# of 257253
FDA issues CRL for Xarelto in ACS:

http://finance.yahoo.com/news/fda-issues-complete-response-letter-214500851.html

This outcome is not especially surprising insofar as the FDA advisory panel rejected Xarelto for this indication by a 6-4 vote (#msg-75925282).

JNJ has a separate NDA submitted for Xarelto in the PCI sub-indication of ACS, a bifurcation of the ACS indication that looks pretty smart in hindsight (#msg-75916451).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now